

IN THE CLAIMS:

This listing of claims below will replace all prior versions, and listings, of claims in the application:

Listing of Claims

Claims 1-3. (canceled).

Claim 4. (currently amended) A method of lowering the blood glucose level which comprises administering an effective dose of a growth hormone secretagogue receptor (GHS-R) antagonist to a patient with diabetes mellitus, wherein said GHS-R antagonist is selected from the group consisting of a ghrelin analog antagonist, [D-Lys-3]-GHRP-6 and [D-Arg-1, D-Phe-5, D-Trp-7, 9, Leu-11] substance P, and wherein said GHS-R antagonist lowers the blood glucose level in the patient.

Claim 5 to 9 (canceled).

Claim 10. (previously presented) A method of claim 4, wherein the GHS-R antagonist is administered centrally or peripherally.

Claims 11 to 13 (canceled).